bioxceltherapeutics.comBioXcel Therapeutics, Inc. (BTAI)

About Overview Management Team Board of Directors Strategic Advisors Product Pipeline Overview Expanded Access News & Media Press Releases Publications Events Media Investors Investor Relations Overview News / Events Overview Press Releases Press Coverage IR Calendar Email Alerts Company Info Overview Presentations Management Team Contacts FAQ Financial Info Overview Balance Sheet Income Statement Cash Flow Financial Results Stock Data Overview Quote Charts Historical Data Analyst Coverage SEC Filings Overview All SEC Filings Annual Reports Quarterly Reports Section 16 Filings Governance Overview Board of Directors Board Committees Governance Documents Business Development Careers Overview Job Openings Contact Innovative Medicine Backed by the Power of Artificial Intelligence BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing artificial intelligence, or AI, approaches to develop transformative medicines in neuroscience and immuno-oncology. About Us Company’s Approach to Drug Development AI-based Drug Development Our neuroscience and immuno-oncology programs utilize our AI approach to drug development. BXCL501 BXCL501 is an investigational, proprietary, orally dissolving, thin film formulation of dexmedetomidine designed for the treatment of agitation and opioid withdrawal symptoms. BXCL701 BXCL701 is an investigational, orally-administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. Latest News May 26, 2021 7:00 AM EDT BioXcel Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences View Release May 19, 2021 7:00 AM EDT BioXcel Therapeutics Announces FDA Acceptance for Filing of NDA for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders I and II View Release May 11, 2021 7:00 AM EDT BioXcel Therapeutics Announces Presentations at the ISBD 2021 Global Annual Conference View Release View all news Sign up for Email Alerts Email Sign Up First Name Last Name Email Address Contact Type: Individual Investor Analyst Broker/Investment Advisor Portfolio Manager Banker/Financing Source Press/Media Consultant Employee Customer/Client Student Other Sign me up for: Press Releases Annual & Quarterly Reports Current Reports Insider Transactions Proxy Information All Filings Sign Up Stock Information BioXcel Therapeutics, Inc. View Investor Relations View Investor Presentation © 2021 BioXcel Therapeutics, Inc. All Rights Reserved. Privacy Policy Disclaimer Sitemap Market Data copyright © 2021 QuoteMedia . Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT =Real-Time, EOD =End of Day, PD =Previous Day. Market Data powered by QuoteMedia . Terms of Use ....